Search
Immune Therapies for Hematologic Disorders
Recently the treatment of hematological and solid malignancies has been revolutionized by the introduction of novel immunotherapeutic strategies.
Read moreStem Cells
Mission:
The goal of the SWG on Stem Cells is to bring together researchers, biologists and clinicians involved in stem cell research to share their recent advances in the field, as well as to train new junior members.
Publications
The EBMT/EHA CAR-T Cell Handbook
Editors: Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele. 2022, ISBN 978-3-030-94352-3 ISBN 978-3-030-94353-0 (eBook).
Renew your membership
If you want to keep enjoying the benefits of EHA membership— from around-the-clock access to EHA Campus to discounts on EHA Congress registration—you'll need to renew your membership.
Read moreEHA-Balkan Hematology Day 2021
EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 2nd edition of the EHA-Balkan Hematology Day.
Read moreEHA-SWG Scientific Meeting on Pediatric Hematology 2022
On April 7-9, 2022 the EHA-SWG Scientific Meeting on Pediatric Hematology was successfully held at the NH Collection Vittorio Veneto hotel in Rome.
Read moreThe International Society on Thrombosis and Haemostasis (ISTH) Hosts its Second Advanced Training Course on Thrombosis and Haemostasis on March 13-16, 2014
The Second Advance Training Course is a follow-up to the successful inaugural course organized in 2011 and attended by 200 professionals. Course speakers include nine international and regional experts in the field of thrombosis and haemostasis.
Read moreEHA-ASH TRTH Joint Oversight Committee
Current committee members
Janis Abkowitz
David Bodine
Chiara Bonini
Ruud Delwel
Mary Dinauer
Terry Fry
Jessica Okosun
Kostas Stamatopoulos
AimTo develop, in collaboration with ASH, translational researchers in Europe and beyond by running the TRTH program while maintaining quality of the program elements by choosing and guiding the faculty…
Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients
Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- »